Pfizer and Moderna will now include more information on the risk of myocarditis on their COVID-19 vaccine labels.

The expanded recommendation is good news for Moderna, Pfizer, and GSK, which all sell RSV vaccines for older adults. Moderna ...

A top official at the Food and Drug Administration recently overruled government scientists on the availability of two ...

FDA vaccine head Vinay Prasad restricted Moderna and Novavax COVID vaccines to high-risk groups, overriding staff advice amid ...

Moderna’s cash flow issues are more immediate than those of its peers, so the new provision could have a greater impact on ...

The RSV vaccine is now recommended for adults aged 50 to 59 who are at a high risk of severe infection.

The label for Moderna's respiratory syncytial virus (RSV) vaccine mResvia has been expanded to include adults aged 18 and over in the US, widening its earlier FDA approval for the over-60s only.